The CYP2C19 genotype and the use of oral contraceptives influence the pharmacokinetics of carisoprodol in healthy human subjects

European Journal of Clinical Pharmacology

Volumn 61, Issue 7, 2005, Pages 499-506

  Bramness, Jørgen G ^a   Skurtveit, Svetlana ^a   Gulliksen, Margaretha ^a   Breilid, Harald ^b,c   Steen, Vidar M ^b,c   Mørland, Jørg ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CARISOPRODOL; CYTOCHROME P450 2C19; DESOGESTREL; DRUG METABOLIZING ENZYME; ETHINYLESTRADIOL; MEPROBAMATE; ORAL CONTRACEPTIVE AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BALANCE DISORDER; CONFIDENCE INTERVAL; DIZZINESS; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; GENOTYPE; HALF LIFE TIME; HUMAN; MALE; MUSCLE TONE; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; SEDATION; SHIVERING; SIDE EFFECT; TREMOR;

AREA UNDER CURVE; ARYL HYDROCARBON HYDROXYLASES; CARISOPRODOL; CHROMATOGRAPHY, LIQUID; CONTRACEPTIVES, ORAL; DRUG INTERACTIONS; GENOTYPE; HUMANS; MASS SPECTROMETRY; MIXED FUNCTION OXYGENASES; MUSCLE RELAXANTS, CENTRAL; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY;

EID: 24044464590     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-005-0970-1     Document Type: Article

References (54)

1. Waddell G, McIntosh A, Hutchinson A, Feder G, Lewis M (1999) Low back pain evidence review, 2nd edn. Royal College of General Practitioners, London
2. Baratta RR (1976) A double-blind comparative study of carisoprodol, propoxyphene, and placebo in the management of low back syndrome. Curr Ther Res Clin Exp 20:233-240
3. Boothby L, Doering P, Hatton R (2003) Carisoprodol: a marginally effective skeletal muscle relaxant with serious abuse potential. Hosp Pharmacy 38:337-345
4. Littrell RA, Hayes LR, Stillner V (1993) Carisoprodol (Soma): a new and cautious perspective on an old agent. South Med J 86:753-756
5. Littrell RA, Sage T, Miller W (1993) Meprobamate dependence secondary to carisoprodol (Soma) use. Am J Drug Alcohol Abuse 19:133-134
6. Bailey DN, Briggs JR (2002) Carisoprodol: an unrecognized drug of abuse. Am J Clin Pathol 117:396-400
7. Elder NC (1991) Abuse of skeletal muscle relaxants. Am Fam Physician 44:1223-1226
8. Bramness J, Sørlid H, Rudberg N, Mørland J, Jacobsen D (2005) Carisoprodol intoxications and serotoninergic symptoms. J Toxicol Clin Toxicol 43:39-46
9. Brandslund I (1976) A case of acute carisoprodol poisoning. Symptoms and metabolism. Ugeskr Laeger 138:281-283
10. Olsen H, Koppang E, Alvan G, Mørland J (1995) Carisoprodol elimination in humans. Ther Drug Monit 16:337-340
11. Dalen P, Alvan G, Wakelkamp M, Olsen H (1996) Formation of meprobamate from carisoprodol is catalysed by CYP2C19. Pharmacogenetics 6:387-394
12. Baselt R (2000) Disposition of toxic dugs and chemicals in man, 5th edn. Chemical Toxicology Institute, Foster City, Calif.
13. Wedlund PJ (2000) The CYP2C19 enzyme polymorphism. Pharmacology 61:174-183
14. Bramness JG, Skurtveit S, Fauske L, Grung M, Molven A, Morland J, Steen VM (2003) Association between blood carisoprodol: meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers: decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects? Pharmacogenetics 13:383-388
15. Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brosen K (1996) Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 51:73-78
16. Buur Rasmussen B, Nielsen T, Brøsen K (1998) Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro. Eur J Clin Pharmacol 54:735-740
17. Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA (1997) Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 25:853-862
18. Gugler R, JC J (1985) Omeprazol inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology 89:1235-1241
19. Andersson T, Cederberg C, Edvardsson G, Heggelund A, Lundborg P (1990) Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther 47:79-85
20. Caraco Y, Tateishi T, Wood A (1995) Interethnic difference in omeprazol's inhibition of diazepam metabolism. Clin Pharmacol Ther 58:62-72
21. Andersson T, Andren K, Cederberg C, Edvardsson G, Heggelund A, Lundborg P (1990) Effect of omeprazole and cimetidine on plasma diazepam levels. Eur J Clin Pharmacol 39:51-54
22. Zomorodi K, Houston JB (1996) Diazepam-omeprazole inhibition interaction: an in vitro investigation using human liver microsomes. Br J Clin Pharmacol 42:157-162
23. Cho J, Yu K, Jang I, Yang B, Shin S, Yim D (2002) Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19. Br J Clin Pharmacol 53:393-397
24. Hagg S, Spigset O, Dahlqvist R (2001) Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. Br J Clin Pharmacol 51:169-173
25. Laine K, Tybring G, Bertilsson L (2000) No sex-related differences but significant inhibition by oral contraceptives of CYP2C19 activity as measured by the probe drugs mephenytoin and omeprazole in healthy Swedish white subjects. Clin Pharmacol Ther 68:151-159
26. Palovaara S, Tybring G, Laine K (2003) The effect of ethinyloestradiol and levonorgestrel on the CYP2C19-mediated metabolism of omeprazole in healthy female subjects. Br J Clin Pharmacol 56:232-237
27. McGready R, Stepniewska K, Seaton E, Cho T, Cho D, Ginsberg A, Edstein M, Ashley E, Looareesuwan S, White N, Nosten F (2003) Pregnancy and use of oral contraceptives reduces biotransformation of proguanil to cycloguanil. Eur J Clin Pharmacol 59:553-557
28. Goldstein JA, Blaisdell J (1996) Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism. Methods Enzymol 272:210-218
29. Ferguson RJ, De Morais SM, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G, Wilkinson GR, Sarich TC, Wright JM, Dayer P, Goldstein JA (1998) A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 284:356-361
30. Laine K, Yasar U, Widen J, Tybring G (2003) A screening study on the liability of eight different female sex steroids to inhibit CYP2C9, 2C19 and 3A4 activities in human liver microsomes. Pharmacol Toxicol 93:77-81
31. Bond A, Lader M (1974) The use of analogue scales in rating subjective feelings. Br J Ed Psychol 47:211-218
32. Bramness J, Skurtveit S, Mørland J (2003) Testing for benzodiazepine inebriation-relationship between benzodiazepine concentration and simple clinical tests for impairment in a sample of drugged drivers. Eur J Clin Pharmacol 59:593-601
33. Christophersen AS, Gulliksen M, Hasvold I, Johansen U, Karinen R, Ripel Å, Krogh M (2001) Screening, confirmation and quantification of drugs of abuse in whole blood by LC-MS (ESI). TIAFT, Prague
34. Grady J, Helms R (1995) Model selection techniques for the covariance matrix for incomplete longitudinal data. Stat Med 14:1397-1416
35. Robertson MD, Marinetti LJ (2003) Carisoprodol - effects on human performance and behavior. Forensic Sci Rev 15:1-8
36. Lamba JK, Dhiman RK, Singh R, Kohli KK (2001) Correlation between omeprazole hydroxylase and CYP2C19 genotype in north Indians. Eur J Clin Pharmacol 57:649-652
37. Chang M, Tybring G, Dahl ML, Gotharson E, Sagar M, Seensalu R, Bertilsson L (1995) Interphenotype differences in disposition and effect on gastrin levels of omeprazole-suitability of omeprazole as a probe for CYP2C19. Br J Clin Pharmacol 39:511-518
38. Klotz U, Schwab M, Treiber G (2004) CYP2C19 polymorphism and proton pump inhibitors. Pharmacol Toxicol 95:2-8
39. Steimer W, Zöpf K, van Amelunxen S, Pfeiffer H, Bachoffer J, Popp J, Messner B, Kissling W, Leucht S (2004) Allele-specific change of concentration and functional gene-dose for the prediction of steady state serum concentrations of amitriptyline and nortriptyline in CYP2C19 and CYP2D6 extensive and intermediate metabolizers. Clin Chem 50:1623-1633
40. Qin XP, Xie HG, Wang W, He N, Huang SL, Xu ZH, Ou-Yang DS, Wang YJ, Zhou HH (1999) Effect of the gene dosage of CYP2C19 on diazepam metabolism in Chinese subjects. Clin Pharmacol Ther 66:642-646
41. Bramness JG, Skurtveit S, Grung M, Mørland J (2000) Centrally acting muscle relaxants: abuse potential and traffic hazards. Tidsskr Nor Lægeforen 120:1966-1969
42. Ronning M (2001) Drug consumption in Norway 1996-2000. Norwegian Medicinal Depot, Oslo
43. Flaten M, Simonsen T, Zahlsen K, Aamo T, Sager G, Olsen H (2004) Stimulant and relaxant drugs combined with stimulant and relaxant information: a study of active placebo. Psychopharmacology 176(3-4):426-434
44. Druid H, Holmgren P (1997) A compilation of fatal and control concentrations of drugs in postmortem femoral blood. J Forensic Sci 42:79-87
45. Bramness J, Skurtveit S, Mørland J (2004) Impairment due to intake of carisoprodol. Drug Alcohol Depend 74:311-318
46. Schulz M, Schmoldt A (1997) Therapeutic and toxic blood concentrations of more than 500 drugs. Pharmazie 52:895-911
47. Winek CL, Wahba WW, Winek CLj, Balzer TW (2001) Drug and chemical blood-level data 2001. Forensic Sci Int 122:107-123
48. Siddiqi M, Jennings C (2004) A near-fatal overdose of carisoprodol (Soma): case report. J Toxicol Clin Toxicol 42:239-240
49. Goldberg D (1969) Carisoprodol toxicity. Mil Med 134:597-601
50. Allen MD, Greenblatt DJ, Noel BJ (1977) Meprobamate overdosage: a continuing problem. Clin Toxicol 11:501-515
51. Zawertailo L, Busto U, Kaplan H, Greenblatt D, Sellers EM (2003) Comparative abuse liability and pharmacological effects of meprobamate, triazolam and butabarbital. J Clin Psychopharmacol 23:269-280
52. Roache JD, Griffiths RR (1987) Lorazepam and meprobamate dose effects in humans: behavioral effects and abuse liability. J Pharmacol Exp Ther 243:978-988
53. Waterloo K, Flaten M, Simonsen T, Olsen H (1997) The effect of carisoprodol on performance on repeatedly administered neuropsychological tests. Hum Psychopharmacol 12:393-396
54. Raffel S, Swink R, Lampton T (1969) The influence of chlorphenesin carbamate and carisoprodol on psychological test scores. Curr Ther Res 11:553-560